Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nplate REMS Precludes Need For Medicare Coverage Restrictions – Amgen

Executive Summary

Amgen's platelet producer Nplate (romiplostim) does not need coverage restrictions from Medicare to ensure its safe use because it is already the subject of an FDA-mandated Risk Evaluation and Mitigation Strategy, the company told CMS in recent comments
Advertisement

Related Content

ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
Advertisement
UsernamePublicRestriction

Register

PS050215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel